PROGENICS PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1988-01-01

Employees: 105

Market Cap: -

Website: http://www.progenics.com

Clinical Trials

Active:3

Completed:7

Trial Phases

3 Phases

Phase 1:3

Phase 2:5

Phase 3:1

Drug Approvals

FDA:1

Drug Approvals

PYLARIFY

Approval Date: Nov 20, 2023

FDA

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 2

5 (55.6%)

Phase 1

3 (33.3%)

Phase 3

1 (11.1%)

Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone

Phase 2

Active, not recruiting

Conditions: Metastatic Prostate Cancer
Castration-resistant Prostate Cancer
Prostatic Neoplasm
Cancer of the Prostate
Progressive mCRPC

Interventions: Drug: I-131-1095
Drug: Enzalutamide

First Posted Date: 2019-05-07

Last Posted Date: 2023-11-22

Lead Sponsor: Progenics Pharmaceuticals, Inc.

Target Recruit Count: 120

Registration Number: NCT03939689

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
🇺🇸
UCLA, Los Angeles, California, United States

and more 24 locations

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer Metastatic
Prostate Cancer Recurrent
Prostate Cancer
Prostate Adenocarcinoma

Interventions: Drug: 18F-DCFPyL
Diagnostic Test: PET/CT Imaging

First Posted Date: 2018-11-14

Last Posted Date: 2021-06-14

Lead Sponsor: Progenics Pharmaceuticals, Inc.

Target Recruit Count: 208

Registration Number: NCT03739684

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Tower Urology, Los Angeles, California, United States
🇺🇸
University of California San Francisco - Helen Diller Cancer Center, San Francisco, California, United States

and more 11 locations

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: 18F-DCFPyL Injection
Diagnostic Test: PET/CT imaging

First Posted Date: 2016-12-05

Last Posted Date: 2021-08-09

Lead Sponsor: Progenics Pharmaceuticals, Inc.

Target Recruit Count: 385

Registration Number: NCT02981368

Locations: 🇺🇸
University of California at San Francisco (UCSF) - Mt. Zion Hospital, San Francisco, California, United States
🇺🇸
Yale University Department of Radiology and Biomedical Imaging, New Haven, Connecticut, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 7 locations